|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000–14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu F, Xu J, Huang Q, Han J, Duan L, Fan J,
Lv Z, Guo M, Hu G, Chen L, et al: The role of interleukin-17 in
lung cancer. Mediators Inflamm. 2016:84940792016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Q, Liu S, Ge D, Zhang Q, Xue Y,
Xiong Z, Abdel-Mageed AB, Myers L, Hill SM, Rowan BG, et al:
Interleukin-17 promotes formation and growth of prostate
adenocarcinoma in mouse models. Cancer Res. 72:2589–2599. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akbay EA, Koyama S, Liu Y, Dries R, Bufe
LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, et al:
Interleukin-17A promotes lung tumor progression through neutrophil
attraction to tumor sites and mediating resistance to PD-1
blockade. J Thorac Oncol. 12:1268–1279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Numasaki M, Fukushi J, Ono M, Narula SK,
Zavodny PJ, Kudo T, Robbins PD, Tahara H and Lotze MT:
Interleukin-17 promotes angiogenesis and tumor growth. Blood.
101:2620–2627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Yi T, Kortylewski M, Pardoll DM,
Zeng D and Yu H: IL-17 can promote tumor growth through an
IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kryczek I, Wei S, Szeliga W, Vatan L and
Zou W: Endogenous IL-17 contributes to reduced tumor growth and
metastasis. Blood. 114:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu FM, Li QL, Gao Q, Jiang JH, Zhu K,
Huang XY, Pan JF, Yan J, Hu JH, Wang Z, et al: IL-17 induces
AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in
hepatocellular carcinoma. Mol Cancer. 10:1502011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen JG, Xia JC, Liang XT, Pan K, Wang W,
Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, et al: Intratumoral
expression of IL-17 and its prognostic role in gastric
adenocarcinoma patients. Int J Biol Sci. 7:53–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang CK, Yang CY, Jeng YM, Chen CL, Wu
HH, Chang YC, Ma C, Kuo WH, Chang KJ, Shew JY and Lee WH:
Autocrine/paracrine mechanism of interleukin-17B receptor promotes
breast tumorigenesis through NF-κB-mediated antiapoptotic pathway.
Oncogene. 33:2968–2977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu HH, Hwang-Verslues WW, Lee WH, Huang
CK, Wei PC, Chen CL, Shew JY, Lee EY, Jeng YM, Tien YW, et al:
Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody
blocks pancreatic cancer metastasis by silencing multiple
chemokines. J Exp Med. 212:333–349. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bie Q, Sun C, Gong A, Li C, Su Z, Zheng D,
Ji X, Wu Y, Guo Q, Wang S and Xu H: Non-tumor tissue derived
interleukin-17B activates IL-17RB/AKT/β-catenin pathway to enhance
the stemness of gastric cancer. Sci Rep. 6:254472016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pfeifer P, Voss M, Wonnenberg B, Hellberg
J, Seiler F, Lepper PM, Bischoff M, Langer F, Schäfers HJ, Menger
MD, et al: IL-17C is a mediator of respiratory epithelial innate
immune response. Am J Respir Cell Mol Biol. 48:415–421. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jungnickel C, Schmidt LH, Bittigkoffer L,
Wolf L, Wolf A, Ritzmann F, Kamyschnikow A, Herr C, Menger MD,
Spieker T, et al: IL-17C mediates the recruitment of
tumor-associated neutrophils and lung tumor growth. Oncogene.
36:4182–4190. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang
J, Liu Y, Yao X, Meng G, Shen N, et al: Alterations in the
microbiota drive interleukin-17C production from intestinal
epithelial cells to promote tumorigenesis. Immunity. 40:140–152.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Sullivan T, Saddawi-Konefka R, Gross E,
Tran M, Mayfield SP, Ikeda H and Bui JD: Interleukin-17D mediates
tumor rejection through recruitment of natural killer cells. Cell
Rep. 7:989–998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin SY, Jian FY, Chen YH, Chien SC, Hsieh
MC, Hsiao PW, Lee WH, Kuo YH and Yang NS: Induction of IL-25
secretion from tumour-associated fibroblasts suppresses mammary
tumour metastasis. Nat Commun. 7:113112016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Z, Chen J, Du X, Cheng H, Wang X and
Dong C: IL-25 blockade inhibits metastasis in breast cancer.
Protein Cell. 8:191–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Furuta S, Jeng YM, Zhou L, Huang L, Kuhn
I, Bissell MJ and Lee WH: IL-25 causes apoptosis of
IL-25R-expressing breast cancer cells without toxicity to
nonmalignant cells. Sci Transl Med. 3:78ra312011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo Y, Yang Z, Su L, Shan J, Xu H, Xu Y,
Liu L, Zhu W, Chen X, Liu C, et al: Non-CSCs nourish CSCs through
interleukin-17E-mediated activation of NF-κB and JAK/STAT3
signaling in human hepatocellular carcinoma. Cancer Lett.
375:390–399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Zhao X, Sun X, Li Y, Wang Z, Jiang
J, Han H, Shen W, Corrigan CJ and Sun Y: Expression of IL-17A, E,
and F and their receptors in human prostatic cancer: Comparison
with benign prostatic hyperplasia. Prostate. 75:1844–1856. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Sheng W, Xiang J, Ye Z and Yang J:
Interleukin-17F suppresses hepatocarcinoma cell growth via
inhibition of tumor angiogenesis. Cancer Invest. 28:598–607. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding L, Hu EL, Xu YJ, Huang XF, Zhang DY,
Li B, Hu QG, Ni YH and Hou YY: Serum IL-17F combined with VEGF as
potential diagnostic biomarkers for oral squamous cell carcinoma.
Tumour Biol. 36:2523–2529. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Forbes SA, Beare D, Gunasekaran P, Leung
K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et
al: COSMIC: Exploring the world's knowledge of somatic mutations in
human cancer. Nucleic Acids Res 43 (Database Issue). D805–D811.
2015. View Article : Google Scholar
|
|
26
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Anstet MJ, Kincead-Beal C,
Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a
collection of 18,000 cancer gene expression profiles. Neoplasia.
9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu T, Jia W, An Q, Cao X and Xiao G:
Bioinformatic analysis of GLI1 and related signaling pathways in
chemosensitivity of gastric cancer. Med Sci Monit. 24:1847–1855.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res 39 (Database Issue). D561–D568. 2011. View Article : Google Scholar
|
|
31
|
Pathan M, Keerthikumar S, Ang CS, Gangoda
L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim
A, et al: FunRich: An open access standalone functional enrichment
and interaction network analysis tool. Proteomics. 15:2597–2601.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Beltran H, Prandi D, Mosquera JM, Benelli
M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV,
Varambally S, et al: Divergent clonal evolution of
castration-resistant neuroendocrine prostate cancer. Nat Med.
22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eirew P, Steif A, Khattra J, Ha G, Yap D,
Farahani H, Gelmon K, Chia S, Mar C, Wan A, et al: Dynamics of
genomic clones in breast cancer patient xenografts at single-cell
resolution. Nature. 518:422–426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Selamat SA, Chung BS, Girard L, Zhang W,
Zhang Y, Campan M, et al: Genome-scale analysis of DNA methylation
in lung adenocarcinoma and integration with mRNA expression. Genome
Res 22 (7). 1197–1211. 2012. View Article : Google Scholar
|
|
39
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Okayama H, Kohno T, Ishii Y, Shimada Y,
Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S,
et al: Identification of genes upregulated in ALK-positive and
EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.
72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gaffen SL: Recent advances in the IL-17
cytokine family. Curr Opin Immunol. 23:613–619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen X, Wan J, Liu J, Xie W, Diao X, Xu J,
Zhu B and Chen Z: Increased IL-17-producing cells correlate with
poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer.
69:348–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu J, Duan Y, Cheng X, Chen X, Xie W,
Long H, Lin Z and Zhu B: IL-17 is associated with poor prognosis
and promotes angiogenesis via stimulating VEGF production of cancer
cells in colorectal carcinoma. Biochem Biophys Res Commun.
407:348–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin Q, Xue L, Tian T, Zhang B, Guo L, Lin
G, Chen Z, Fan K and Gu X: Prognostic value of serum IL-17 and VEGF
levels in small cell lung cancer. Int J Biol Markers. 30:e359–e363.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pan B, Che D, Cao J, Shen J, Jin S, Zhou
Y, Liu F, Gu K, Man Y, Shang L and Yu Y: Interleukin-17 levels
correlate with poor prognosis and vascular endothelial growth
factor concentration in the serum of patients with non-small cell
lung cancer. Biomarkers. 20:232–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang XF, Zhu YT, Wang JJ, Zeng DX, Mu CY,
Chen YB, Lei W, Zhu YH and Huang JA: The prognostic value of
interleukin-17 in lung cancer: A systematic review with
meta-analysis based on Chinese patients. PLoS One. 12:e01851682017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wei L, Wang H, Yang F, Ding Q and Zhao J:
Interleukin-17 potently increases non-small cell lung cancer
growth. Mol Med Rep. 13:1673–1680. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin
S, Cao S, Che D, Liu F and Yu Y: Interleukin-17 promotes
angiogenesis by stimulating VEGF production of cancer cells via the
STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep.
5:160532015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang Q, Duan L, Qian X, Fan J, Lv Z,
Zhang X, Han J, Wu F, Guo M, Hu G, et al: IL-17 promotes angiogenic
factors IL-6, IL-8, and Vegf production via Stat1 in lung
adenocarcinoma. Sci Rep. 6:365512016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li Q, Han Y, Fei G, Guo Z, Ren T and Liu
Z: IL-17 promoted metastasis of non-small-cell lung cancer cells.
Immunol Lett. 148:144–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao
JJ, Weng DS, Pan QZ, Wang DD, Jiang SS, et al: IL-17A promotes
immune cell recruitment in human esophageal cancers and the
infiltrating dendritic cells represent a positive prognostic marker
for patient survival. J Immunother. 36:451–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Punt S, van Vliet ME, Spaans VM, de Kroon
CD, Fleuren GJ, Gorter A and Jordanova ES: FoxP3(+) and IL-17(+)
cells are correlated with improved prognosis in cervical
adenocarcinoma. Cancer Immunol Immunother. 64:745–753. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
He Y, Du Y, Wei S, Shi J, Mei Z, Qian L,
Chen Z and Jie Z: IL-17A and IL-17F single nucleotide polymorphisms
associated with lung cancer in Chinese population. Clin Respir J.
11:230–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ma QY, Chen J, Wang SH, Wu N, Hao ZH and
Chen XF: Interleukin 17A genetic variations and susceptibility to
non-small cell lung cancer. APMIS. 123:194–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kaabachi W, ben Amor A, Kaabachi S,
Rafrafi A, Tizaoui K and Hamzaoui K: Interleukin-17A and −17F genes
polymorphisms in lung cancer. Cytokine. 66:23–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li Z, Liu Y, Cao D, Jiang M and Luo F:
IL-17A and IL-17F polymorphisms and gastric cancer risk: A
meta-analysis. Genet Mol Res. 14:7008–7017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wróbel T, Gębura K, Wysoczańska B, Jaźwiec
B, Dobrzyńska O, Mazur G, Kuliczkowski K and Bogunia-Kubik K:
IL-17F gene polymorphism is associated with susceptibility to acute
myeloid leukemia. J Cancer Res Clin Oncol. 140:1551–1555. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Omrane I, Baroudi O, Bougatef K, Mezlini
A, Abidi A, Medimegh I, Stambouli N, Ayari H, Kourda N, Uhrhammer
N, et al: Significant association between IL23R and IL17F
polymorphisms and clinical features of colorectal cancer. Immunol
Lett. 158:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cheng S, Shao Z, Liu X, Guo L, Zhang X, Na
Q, Chen X, Ma Y, Zheng J, Song B and Liu J: Interleukin 17A
polymorphism elevates gene expression and is associated with
increased risk of nonsmall cell lung cancer. DNA Cell Biol.
34:63–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rožman P and Švajger U: The tolerogenic
role of IFN-γ. Cytokine Growth Factor Rev. 41:40–53. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Xu C, Hao K, Yu L and Zhang X: Serum
interleukin-17 as a diagnostic and prognostic marker for non-small
cell lung cancer. Biomarkers. 19:287–290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xu B, Guenther JF, Pociask DA, Wang Y,
Kolls JK, You Z, Chandrasekar B, Shan B, Sullivan DE and Morris GF:
Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung
Cell Mol Physiol. 307:L497–L508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu
YM, Kong QF, Wang JH, Zhang Y, Xu XY and Li HL: Effects of IL-17A
on the occurrence of lung adenocarcinoma. Cancer Biol Ther.
12:610–616. 2014. View Article : Google Scholar
|
|
65
|
Numasaki M, Watanabe M, Suzuki T,
Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze
MT, Kolls JK and Sasaki H: IL-17 enhances the net angiogenic
activity and in vivo growth of human non-small cell lung cancer in
SCID mice through promoting CXCR-2-dependent angiogenesis. J
Immunol. 175:6177–6189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhao C, Li Y, Zhang W, Zhao D, Ma L, Ma P,
Yang F, Wang Y, Shu Y and Qiu W: IL17 induces NSCLC A549 cell
proliferation via the upregulation of HMGA1, resulting in an
increased cyclin D1 expression. Int J Oncol. Mar 7–2018.DOI:
10.3892/ijo.2018.4307.
|
|
67
|
Chen X, Xie Q, Cheng X, Diao X, Cheng Y,
Liu J, Xie W, Chen Z and Zhu B: Role of interleukin-17 in
lymphangiogenesis in non-small-cell lung cancer: Enhanced
production of vascular endothelial growth factor C in
non-small-cell lung carcinoma cells. Cancer Sci. 101:2384–2390.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
You R, DeMayo FJ, Liu J, Cho SN, Burt BM,
Creighton CJ, Casal RF, Lazarus DR, Lu W, Tung HY, et al: IL17A
regulates tumor latency and metastasis in lung adeno and squamous
SQ.2b and AD.1 cancer. Cancer Immunol Res. 6:645–657. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gu K, Li MM, Shen J, Liu F, Cao JY, Jin S
and Yu Y: Interleukin-17-induced EMT promotes lung cancer cell
migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer
Res. 5:1169–1179. 2015.PubMed/NCBI
|
|
70
|
Kulig P, Burkhard S, Mikita-Geoffroy J,
Croxford AL, Hövelmeyer N, Gyülvészi G, Gorzelanny C, Waisman A,
Borsig L and Becher B: IL17A-mediated endothelial breach promotes
metastasis formation. Cancer Immunol Res. 4:26–32. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chang SH, Mirabolfathinejad SG, Katta H,
Cumpian AM, Gong L, Caetano MS, Moghaddam SJ and Dong C: T helper
17 cells play a critical pathogenic role in lung cancer. Proc Natl
Acad Sci USA. 111:5664–5669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q,
Ren F, Liao H, Pu Q, Wang T and You Z: Interleukin-17 and
prostaglandin E2 are involved in formation of an M2
macrophage-dominant microenvironment in lung cancer. J Thorac
Oncol. 7:1091–1100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yang YF, Lee YC, Lo S, Chung YN, Hsieh YC,
Chiu WC and Yuan SF: A positive feedback loop of IL-17B-IL-17RB
activates ERK/β-catenin to promote lung cancer metastasis. Cancer
Lett. 422:44–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liao C, Yu ZB, Meng G, Wang L, Liu QY,
Chen LT, Feng SS, Tu HB, Li YF and Bai L: Association between
Th17-related cytokines and risk of non-small cell lung cancer among
patients with or without chronic obstructive pulmonary disease.
Cancer. 121 (Suppl 17):S3122–S3129. 2015. View Article : Google Scholar
|
